文献速递肝病

白细胞比值是肝硬化急性失代偿和慢加急性肝衰竭患者死亡率的生物标志物

Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure.
PubMed 文献 · Aliment Pharmacol Ther · 2020-07-19

研究纳入四国四中心926例肝硬化急性失代偿或慢加急性肝衰竭患者,入院时及48小时检测外周血白细胞比值。中性粒细胞-淋巴细胞比值(NLR)和单核细胞-淋巴细胞比值(MLR)在院内死亡患者中升高,NLR>30与慢加急性肝衰竭患者90天死亡率80%相关,但预测准确性仅见于使用流式细胞术的中心。

要点

  • NLR和MLR在肝硬化急性失代偿和慢加急性肝衰竭院内死亡患者中升高。
  • 多因素分析中NLR独立于CLIF-SOFA或MELD保持统计学显著性。
  • NLR>30与慢加急性肝衰竭患者90天死亡率80%相关,但与急性失代偿无关。

核心结论

  • 白细胞比值是慢加急性肝衰竭结局的简单且稳健的生物标志物,与CLIF-SOFA评分相当,但依赖于白细胞定量方法。
  • NLR和MLR可能可用作急性恶化肝硬化患者死亡预测的筛查工具。

研究设计与样本

  • 从三个国家的四个中心招募肝硬化急性失代偿和慢加急性肝衰竭患者。
  • 共研究926例患者,其中562例(61%)为男性,中位年龄55(25-94)岁。
  • 入院时及48小时检测外周血白细胞分类,三个中心使用流式细胞术。

主要发现

  • 总体350例(37%)未存活至出院。
  • NLR和MLR在急性失代偿和慢加急性肝衰竭院内死亡患者中升高。
  • 多因素分析中NLR独立于CLIF-SOFA或MELD保持统计学显著性。
  • NLR>30与慢加急性肝衰竭患者90天死亡率80%相关,但与急性失代偿无关。
  • 在酒精相关肝病和疑似脓毒症的亚组敏感性分析中,NLR和MLR对死亡预测保持统计学稳健的准确性。

局限性

  • 显著的预测准确性仅见于使用流式细胞术的中心,提示结果依赖于白细胞定量方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with cirrhosis, progression to acute decompensation (AD) and acute-on-chronic liver failure (ACLF) has been associated with poor prognosis. Differential leucocyte ratios might predict mortality in systemic inflammatory conditions. AIM: To evaluate differential leucocyte ratios as prognostic biomarkers in patients with cirrhosis. METHODS: Patients with AD and ACLF were recruited from four centres in three countries. Peripheral blood differential leucocytes were measured (three centres using flow cytometry) on hospital admission and at 48 hours. Ratios were correlated to model for end-stage liver disease (MELD), chronic liver failure-sequential organ failure (CLIF-SOFA), suspected/culture-positive bacterial infection and survival. RESULTS: Nine hundred twenty-six patients (562 (61%) male, median age 55 (25-94) years) were studied. Overall, 350 (37%) did not survive to hospital discharge. Neutrophil-lymphocyte ratio (NLR) and monocyte-lymphocyte ratio (MLR) were elevated in patients with AD and ACLF who died during their hospital stay. On multivariate analysis NLR retained statistical significance independently of CLIF-SOFA or MELD. NLR >30 was associated with an 80% 90-day mortality in patients with ACLF but not AD. On sensitivity analysis for subgroups (alcohol-related liver disease and suspected sepsis), NLR and MLR retained statistically robust accuracy for the prediction of mortality. Significant predictive accuracy was only observed in centres using flow cytometry. CONCLUSION: Leucocyte ratios are simple and robust biomarkers of outcome in ACLF, which are comparable to CLIF-SOFA score but dependent on leucocyte quantification method. NLR and MLR may be used as screening tools for mortality prediction in patients with acutely deteriorating cirrhosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bernsmeier C, Cavazza A, Fatourou EM, et al. Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Aliment Pharmacol Ther. 2020. PMID: 32683724. doi:10.1111/apt.15932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。